CTSS and neoplasm: The significant part of the current drug design is the cleavage of the pro-drug AMP-001-003 by the tumor specific enzyme Cathepsin B which releases tocopheryl derivatives inside the cancer cells which induces cell death in Cathepsin B positive cancer cells predominantly sparing normal cells.